Augmedix, Inc. (NASDAQ:AUGX) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET

Company Participants

Caroline Paul - Investor Relations

Manny Krakaris - Chief Executive Officer and Board Member

Paul Ginocchio - Chief Financial Officer

Conference Call Participants

Ryan Daniels - William Blair

Marc Wiesenberger - B Riley FBR

Brooks O’Neil - Lake Street Capital Markets

Allen Klee - Maxim Group

Operator

Hello and welcome to the Augmedix, Inc. 2022 First Quarter Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity to ask questions. [Operator Instructions] Please note, today’s event is being recorded.

And now I would like to turn the conference over to Caroline Paul, Investor Relations. Please go ahead, ma’am.

Caroline Paul

Thank you, and thank you all for participating in today’s call. Joining me are Manny Krakaris, Chief Executive Officer; and Paul Ginocchio, Chief Financial Officer. Earlier today, Augmedix released financial results for the quarter ended March 31, 2021. A copy of the press release is available on the company’s website.

Before we begin, I’d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. These forward-looking statements are based upon our current estimates and various assumptions and involve material risks and uncertainties that could cause actual results or events to materially defer from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors and management discussion and analysis of financial condition and results of operations in our most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, and similar disclosures and subsequent reports filed with the SEC.

This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 09, 2022. Augmedix disclaims any intention or obligation accept as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

And with that, I’ll turn the call over to Manny.